Comparisons of Adherence to Antiretroviral Therapy in a High-Risk Population in China: A Systematic Review and Meta-Analysis

Zhou Huan1,2, Wang Fuzhi2, Liu Lu2, Zhang Min2, Chen Xingzhi2, Jin Shiyang1*

1 The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, 233000, P. R. China, 2 Health Management Department, Bengbu Medical College, Bengbu, Anhui, 233000, P. R. China

* jsybbmc@163.com

Abstract

Background

Reports on antiretroviral therapy (ART) adherence are scarce in China; we performed this meta-analysis to estimate ART adherence rates in different populations at high risk for HIV transmission in China.

Methods

We searched PubMed, Chinese Biomedical Literature Database (Chinese), China National Knowledge Infrastructure (Chinese), and Wanfang (Chinese) to identify studies published from January 1985 to May 2015. We used random-effects meta-analysis to calculate weighted mean estimates across studies and 95% CIs. Data were pooled with proportions transformed prior to pooling using the Freeman–Tukey double arcsine transformation and then back transformed to the original scale. We calculated the I² (and its 95% confidence intervals) and τ² to assess between-study heterogeneity.

Results

We identified 36 eligible articles, including 6885 HIV-positive individuals, reporting ART adherence. Pooled analysis produced an estimate of 77.61% (95% CI = 71.63–83.08) of patients with HIV with adequate adherence; however, high heterogeneity was observed between studies (I² = 96.60%, 95%CI = 96.00–97.20%; τ² = 0.16). Three studies, which included 149 old HIV-infected patients, reported the highest ART adequate adherence rate (89.39%, 95% CI = 72.01–99.26) with high heterogeneity between the studies (I² = 86.20%, 95%CI = 60.00–95.20%; τ² = 0.13). While, only two studies, which included 143 heterosexual transmission group (HTG) patients, reported the lowest ART adequate adherence rate (51.55%, 95% CI = 41.33–61.71) with low heterogeneity between the studies (I² = 31.3%, τ² = 0.007). In the multivariable meta-regression model, high-risk populations was the main factor explaining heterogeneity (variance explained 28.14%).
Conclusions

ART adherence in some high-risk populations (e.g., heterosexual transmission group) is below the recommended levels for maintaining virologic suppression. It is crucial to develop comprehensive intervention strategies to promote ART adherence in high-risk populations and effectively prevent the spread of HIV/AIDS in China.

Introduction

Latest data shows an estimated 35.3 million people lived with HIV, of which 9.7 million people in low-income and middle-income countries were receiving antiretroviral therapy (ART) in 2012. Breakthroughs in the "treatment as prevention" strategy, e.g. using ART in pregnant women, people with HIV or with pre-exposure prophylaxis, have resulted in significant reduction in HIV transmission rate, and thus are very important for public health[1]. HIV ART with adequate adherence is conventionally the most effective prevention strategy, known as “treatment as prevention”, due to its significant association with a reduced HIV transmission rate. Furthermore, ART can help HIV-infected patients restore immune function, prolonging life and improving the quality of life[2]. Adequate adherence to ART plays an important role in sustaining viral suppression, preventing the development of disease and decreasing the mortality rate. Drug resistance quickly occurs during the therapeutic process due to poor adherence, which may reduce treatment efficacy, promote disease progression, and increase the risk of transmission [3]. However, many HIV-infected individuals do not achieve or maintain high levels of adherence. Globally, nearly 40% of HIV-infected patients did not maintain an adherence rate higher than 90% in 2011[4].

China is the most HIV-affected region in Asia. HIV epidemics in China tend to be concentrated among members of groups at high risk of acquiring or spreading HIV[5]. However, no systematic review of the ART adherence in China has been performed. Further, access to antiretroviral therapy and adherence in different populations may vary, and no systematic review of comparisons and variations in ART adherence between different populations has been performed.

We performed this meta-analysis to provide a pooled proportion of HIV-infected patients with adequate ART adherence in different high-risk populations to prevent the spread of HIV/AIDS in China. We also provide comparisons of ART adherence between these important populations.

Methods

Search Strategy and Selection Criteria

We searched PubMed, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), and Wanfang (Chinese) to identify any study in each database published from January 1985 to May 2015. The following detail search strategy was used in PubMed: (HIV or “human immune” or “acquired immunodeficiency syndrome”) and (“China” or “Chinese”) and (“adherence” or “compliance” or “pill counts”) and (“ART” OR “HAART” OR “antiretroviral”). The same search strategies were used for each database. No language restriction was placed on the search process. In addition, we also screened the references of the retrieved paper. If the eligible papers were not obtained, we would contact the corresponding author of the paper for detailed information via e-mail.

Only descriptive epidemiological studies that reported ART adherence in HIV-positive specific groups, such as pregnant women, children, former commercial and plasma donors (FCPD), injection drug users (IDUs), men who have sex with men (MSM), heterosexual
transmission group (HTG), were eligible. We excluded qualitative studies, literature reviews, case studies, cost-effectiveness studies, meetings, discussions, editorials, research overviews, book reviews, letters, and news articles. We excluded studies that did not provide usable data, had fewer than 30 participants and were conducted in countries outside China.

**Study Selection and Data Extraction**

Two authors (ZH and WFZ) independently screened the titles and abstracts of all of the identified studies. For each study, one reviewer (LL) extracted the data and a second reviewer (ZM) checked the accuracy. Disagreements would be discussed and resolved by a third investigator (CXZ) if these two investigators could not reach a consensus. For the 36 studies included here, there were no disagreements between the first reviewer (LL) and the second reviewer (ZM). Fig 1 shows the flowchart for selecting articles [6–41].

We developed a data abstraction form and extracted the following data from the eligible studies: studies characteristics (authors, years, design, and study regions), study population (age, sex, and sample size), ART regimen, adherence threshold (e.g., 90%, 95%, 100%), methods of outcomes measurement, and adherence assessor. The population was divided into pregnant women, children, FCPD, IDUs, FSP of HIV-positive individuals, MSM, and TB/HIV co-infected people. We also obtained data from the website of the Chinese administrative region; these data were used to categorize regions (eastern China, south-central China, north China, northwest China, southwestern China, and northeast China) and the gross domestic product in $US per individual in 2013 (low income (<$5520), low-middle income ($5635–6750), high-middle income ($6892–9961), and high income (>10,915)[42,43].

**Quality Assessment**

We used the Agency of Healthcare Research and Quality (AHRQ) assessment to assess the quality of the eligible literature. The AHRQ is an 11-item questionnaire with three-options for each item, and the total score of the AHRQ is 11. Article quality was assessed as low (from 0 to 3), moderate (from 4 to 7), or high (from 8 to 11)[44].

**Statistical Analysis**

Adequate adherence was defined as the proportion of people who reported ≥90% adherence to ART, which was referred in each study as the effect size index (ES). Random-effects meta-analysis was used to calculate weighted mean estimates across studies and 95% CIs, because random-effects models are more conservative and provide better estimates with wider confidence [45]. Data were pooled with proportions transformed prior to pooling using the Freeman–Tukey double arcsine transformation and then back transformed to the original scale[46]. We calculated the I² (and its 95% confidence intervals) and tau² to assess between-study heterogeneity, and H² (and its 95% confidence intervals) to assess within-study heterogeneity [47,48].

Subgroup analyses and meta-regression analyses were used to explore potential heterogeneity in the following categories: study regions (eastern China, south China, south-central China, north China, northwest China, southwestern China, and northeast China), publication year, study design (observational or interventional study), adherence threshold (90–99% and 100%), measure of adherence (single self-reported, combined method of two or more single measure methods including self-reported, pill count, checking medical records, and clinic staff monitoring in the whole study process)), sample size (≤100 and >100), and study quality score (<8 and ≥8). The subgroup analyses in MSM, FCPD, and HTG of HIV-infected patients were not performed because that the number of studies (n≤2) in these subgroup were too small.
To establish the robustness of the outcome by sensitivity analyses, we applied a fixed effects model, excluded studies with a low number of participants\(^{49}\), and excluded studies with a low quality score\(^{19}\). A funnel plot was used to explore publication bias. Funnel-plot asymmetry was further assessed by a Begg’s test and Egger’s linear regression test\(^{50}\). We performed all analyses using Stata software (version 13.0) and R software (version 2-15-2).

Results

Characteristics of Included Studies

We identified 4365 papers from database searches and 92 papers through Internet, hand, and reference list searches. During the abstract screening, 3955 papers were excluded, leaving 502 full-text papers to be assessed for eligibility. Finally, we included 36 papers in this meta-analysis (Fig 1).
Table 1 notes the characteristics of the 36 eligible studies. Most studies were conducted in south-central China (n = 17, 47.22%), followed by south-western China (n = 8, 22.22%), north-west China (n = 4, 11.11%), and trans-regional cities (n = 4, 11.11%). Adherence was most commonly reported in studies of pregnant women (n = 14, 38.89%), followed by IDU (n = 9, 25%), children (n = 4, 11.11%) and elderly patients (n = 3, 8.33%). Most studies (n = 28, 77.78%) were observational, and 8 (22.22%) were interventional studies. 10 (27.78%) studies used a self-reported adherence rate, whereas 26 (72.22%) used combined method of two or more single measure methods including self-reported, pill count, checking medical records, and clinic staff monitoring in the whole study process.

Table 1 presents the study quality score assessed using the AHRQ; 12 (33.33%) were scored as high quality, and 24 (66.67%) were scored as moderate quality.

Overall Adherence to Antiretroviral Therapy

Thirty-six studies, which included 6885 HIV-positive individuals, reported ART adherence (Fig 2). Approximately 77.61% (95% CI = 71.63–83.08) of HIV patients had a high level of adherence; however, high levels of heterogeneity were observed between studies (I^2 = 96.6%, 95%CI = 96%-97.2%; tau^2 = 0.1597; H = 5.44, 95%CI = 4.98–5.95).

ART Adherence Rate by Different Subgroups

The ART adequate adherence rate varied widely between different high-risk populations (Fig 2). Three studies, which included 149 old HIV-infected patients, reported the highest ART adequate adherence rate (95.5%, 95% CI = 41.33–61.71) with low heterogeneity between the studies (I^2 = 31.3%, tau^2 = 0.007).

A total of 14 studies reported ART adequate adherence rate in the subgroup of pregnant women, and the rate was 83.48% (95% CI = 74.72–94.91); however, high heterogeneity was observed between the studies (I^2 = 98.20%, 95%CI = 97.7–98.6; tau^2 = 0.168). The subgroup analyses in pregnant women were also performed, and we found that the adequate adherence rate in pregnant women continually increased from 79.18% (95% CI = 63.80–92.2) in 2008 to 95.65% (95% CI = 89.27–99.45) in 2014 (Table 2). The region with the highest adherence rate in pregnant women was south-central China (96.05%, 95% CI = 83.13–100), followed by south-western China (85.68%, 95% CI = 74.18–93.93) and northwest China (66.23%, 95% CI = 62.27–69.13). The studies with small sample size reported higher adherence rate (95.89%, 95% CI = 87.93–99.94%) than that in studies with large sample size (77.45%, 95% CI = 66.06–87.09%) in pregnant women (Table 2).

A subgroup analysis of ART adherence rate in IDUs was also performed (Table 2). In IDUs, two studies reported the highest adherence rate in northwest China (71.61%, 95% CI: 44.38–92.40) with high heterogeneity between the studies (I^2 = 92.4%, tau^2 = 0.147); while only one studies reported the adherence rate in southwest China, which reported the lowest adherence rate (46.08%, 95% CI: 36.47–55.84). Analyses of ART adherence rate in elderly and pediatric patient subgroups were also performed. However, no significant variations were observed between the subgroups in publication year, regions, and study quality (Table 2). Moreover, the subgroup analyses in MSM, FCPD, and HTG were not performed because only two studies were available for these specific groups.
Table 1. Characteristics of Studies Included in the Meta-Analysis. Note: & Quality score assessed by Agency of Healthcare Research and Quality (AHRQ); $ Income level is divided to high income (>10915), high-middle income (6892–9961), low-middle income, low income (<5520) according to GDP (in $US per head); FCPD = former commercial and plasma donors; IDU = injection drug users; MSM = men who have sex with men; HTG = heterosexual transmission group; OBS = observational study; INT = interventional study; cART = combined antiretroviral therapy; sdNVP = single-dose nevirapine; AZT = zidovudine; D4T = stavudine; DDI = dideoxyinosine; NVP = nevirapine; EFV = efavirenz; 3TC = Lamivudine; LPV/r = Lopinavir/ritonavir; TDF = tenofovir disoproxil fumarate.

| Study (years) | study years | No of participants | Study design | Region | Income level | cART regimens | Adherence Assessor | Adherence (%); Threshold for Measurement | Scores of study quality |
|---------------|-------------|-------------------|-------------|--------|--------------|---------------|-------------------|-----------------------------------------------|----------------------|
| Wang YZ (2008) | 2005–2006 122 pregnant women | OBS Southwestern China | Low income | AZT+NVP; sdNVP | Patient or physician | 100%; doses taken from 28 weeks of gestation | 8 |
| Wang YZ (2008) | 2005–2007 158 pregnant women | OBS Southwestern China | Low income | D4T+3TC+NVP/EFV;AZT+NVP; sdNVP | Patient or physician | 100%; doses taken from 28 weeks of gestation | 8 |
| Pang J (2009) | 2005–2008 110 pregnant women | OBS South-central China | Low income | Three drugs or two drugs | Clinic staff | 100%; doses taken from 28 weeks of gestation | 5 |
| Wang YZ (2008) | 2005–2007 167 pregnant women | OBS Southwestern China | Low income | D4T+3TC+NVP/EFV;AZT+NVP; sdNVP | Medical record | 100%; doses taken from 28 weeks of gestation | 8 |
| Wang LH (2009) | 2004–2008 312 pregnant women | OBS Trans-regional | Low income | standard therapeutic regimen for pregnant women | Clinic staff | 100%; doses taken from 28 weeks of gestation | 7 |
| Wang Q (2011) | 2005–2006 1490 pregnant women | OBS Trans-regional | Low income | D4T+3TC+NVP/EFV;AZT+NVP; sdNVP | Patient or physician | 100%; doses taken from antenatal to postpartum | 8 |
| Gui XZ (2012) | 2006–2010 208 pregnant women | OBS South-central China | Low income | AZT+3TC+NVP/EFV | Self-reported | 100%; doses taken from antenatal to postpartum | 6 |
| Hu HM (2012) | 2010–2011 678 pregnant women | INT Southwestern China | Low income | AZT+3TC+LPV/r;AZT+3TC+EFV/NVP | Patient or physician | 100%; doses taken from antenatal to postpartum | 8 |
| Li AJ (2012) | 2006–2008 158 pregnant women | OBS Southwestern China | Low income | AZT+3TC+NVP/EFV;AZT+NVP; sdNVP | Medical record | 95%; based on past 1 month | 6 |
| Chen SP (2013) | 2012 30 pregnant women | INT South-central China | Low-middle income | No report | Self-reported | 95; doses taken in past 1 months | 5 |
| AliKia. Shawuli (2013) | 2010–2012 1303 pregnant women | OBS Northwestern China | Low-middle income | AZT; 3TC+NVP; sdNVP; AZT+3TC; AZT+3TC+LPV/r; AZT+3TC+EFV/ NVP | Patient and physician | 100%; doses taken from antenatal to postpartum | 6 |
| Wang Q (2013) | 2005–2008 1414 pregnant women | OBS Trans-regional | Low income | Standard therapeutic regimen for pregnant women and newborn | Medical record and patient report | 100%; doses taken from antenatal to postpartum | 8 |
| Wu HP (2013) | 2009–2011 314 pregnant women | OBS Southwestern China | Low income | Standard therapeutic regimen for pregnant women | Patient and physician | 100%; doses taken from antenatal to postpartum | 7 |
| Li ZJ (2014) | 2005–2013 69 pregnant women | OBS Southwestern China | Low income | AZT+3TC+LPV/r | Patient and physician | 100%; doses taken from antenatal to postpartum | 4 |
| Yu RH (2007) | 2006 72 FCPD | OBS Eastern China | Low income | D4T+3TC+NVP/ATV;D4T+DDI+NVP;3TC+DDI+EFV | Self-reported | 95%; No. of pills taken/pills prescribed in past four days | 8 |
| Yuan Y (2012) | 2003–2009 606 FCPD | OBS South-central China | Low income | AZT/D4T+DDI+NVP/EFV;AZT/D4T+3TC+NVP/EFV | Patient or physician | 90%; doses taken in past 1 month | 6 |

(Continued)
| Study (years) | No of participants | Study design | Region | Income level* | cART regimens | Adherence Assessor | Adherence (%); Threshold for Measurement | Scores of study quality* |
|---------------|--------------------|--------------|--------|---------------|----------------|-------------------|------------------------------------------|-------------------------|
| Lu J (2008)   | 62 IDUs            | OBS          | Northwest China | Low-middle income | D4T+3TC+NVP/EFV;AZT+3TC+NVP | Self-reported | 95%; based on past 1 week | 8 |
| Wang HH (2008)| 111 IDUs          | OBS          | South-central China | Low income | AZT+3TC+NVP/EFV; | Self-reported | 90%; No. of the doses taken/No. of doses prescribed in past 1 month | 7 |
| Zhou J (2008) | 116 IDUs          | INT          | South-central China | Low-middle income | AZT+3TC+NVP/EFV; | Clinic staff and pill count | >95%; No. of pills taken/No. of pills prescribed over prior 1 month | 9 |
| Lu J (2008)   | 180 IDUs          | OBS          | Trans-regional | Low-middle income | D4T+3TC+NVP/EFV;AZT+3TC+NVP/EFV | Self-reported | 95%; No. of doses recorded/total No. of doses prescribed in the past 1 week | 9 |
| Yang CB (2010)| 102 IDUs          | OBS          | Southwestern China | Low income | D4T+3TC+NVP;AZT+3TC+NVP/EFV | Patient or physician | 100%; based on past 12 months | 6 |
| Su FQ (2011)  | 60 IDUs           | INT          | South-central China | Low income | No report | Self-reported | 100%; doses taken in past 1 month | 4 |
| Lu J (2013)   | 180 IDUs          | OBS          | Northwest China | Low-middle income | No report | Pill count | 95%; No. of pills taken/No. of pills prescribed | 7 |
| Qin YL (2013) | 73 IDUs           | INT          | South-central China | High-middle income | AZT+3TC+NVP/EFV;D4T+3TC+NVP/EFV; | Self-reported | 100%; doses taken/doses prescribed in the past 1 week | 6 |
| Ye HL (2013)  | 60 IDUs           | OBS          | South-central China | Low income | AZT+3TC+NVP/EFV/LPV/r;D4T+3TC+NVP/EFV/TDF+3TC+LPV/r | Clinic staff | 100%; doses taken in past 6 months | 6 |
| Deng MH (2012)| 72 elderly patients | INT        | South-central China | Low income | No report | Patient or physician | 100; doses taken in past 1 month | 5 |
| Liu JR (2013) | 63 elderly patients | OBS        | South-central China | Low income | No report | Patient and physician | 100%; doses taken in past 3 months | 4 |
| Lu MR (2014)  | 100 elderly patients | INT        | South-central China | Low income | No report | Clinic staff and pill count | 100%; doses taken/doses prescribed in the past 6 months | 4 |
| Zhou YF (2012)| 200 MSM           | INT          | South-central China | Low-middle income | No report | Self-reported | 100%; doses taken | 8 |
| Qiao JK (2014)| 200 MSM           | OBS          | Northern China | Low income | AZT/D4T+3TC+NVP/EFV | Clinic staff and pill count | 95%; No. of pills taken/No. of pills prescribed | 7 |
| Liu AW (2007) | 40 children       | OBS          | Eastern China | Low income | D4T+3TC+NVP/EFV;AZT+3TC+NVP/EFV; | Clinic staff | 100%; based on past 1 month | 6 |
| Chang YL (2009)| 46 children      | OBS          | Northwest China | Low-middle income | D4T+3TC+NVP/EFV;AZT+3TC+NVP/EFV | Patient or physician | 100%; based on past 3 months | 5 |

(Continued)
Meta-Regression Analyses

The meta-regression for ART adherence is shown in Table 3. In the univariate meta-regression model, high-risk populations, sample size, and study quality score were associated with ART adherence rate. In the multivariable model, high-risk populations was the main factors explaining heterogeneity (variance explained 28.14%). Sample size and study quality score did not retain significance.

Sensitivity Analyses

We performed sensitivity analyses of the ART adherence rate by applying a fixed effects model, and we found similar adherence rate between random-effect mode and fixed-effect mode in the overall analysis and the subgroup analyses (Fig 2). Moreover, excluded studies with a low number of participants, and excluded studies with a low quality score both produced similar adherence rate.

Evaluation of Publication Bias

We produced funnel plots and visually examined these plots for signs of asymmetry. We generated funnel plots to assess publication bias of the ART adherence rate. For overall ART adherence rate, the asymmetry observed in the funnel plots was minimal (Fig 3). We also assessed funnel plot asymmetry using the Egger’s linear regression test. No publication bias was observed in the adherence estimate across different specific populations (P>0.05) (Table 4).

Discussion

To our knowledge, this is the first meta-analysis to summarize and compare pooled ART adherence between different high-risk populations in China. We found that approximately 76.6% of HIV-infected individuals at high risk of transmitting HIV have adequate ART adherence. Significant differences in adherence rate were observed between different populations, and the highest ART adherence rate was observed in elderly patients, followed by children, MSM, pregnant women, IDUs, FCPD, and HTG. The adequate ART adherence rate in China was higher than that in India (70%), Spain (50%), and North American countries (57%) and similar to African countries[51–53]. Our findings indicated that reaching and maintaining
high levels of ART adherence remain major issues in China, especially in some high-risk populations with lower adherence.

Fig 2. Meta-analyses of adequate adherence to antiretroviral therapy in special population groups in China. Adequate adherence was defined as the proportion of people who reported ≥90% adherence to ART, which was estimated in each study as the effect size index (ES). doi:10.1371/journal.pone.0146659.g002
Table 2. Subgroup Analyses of Adherence (95%CI) to Antiretroviral Therapy in Special Population Groups in China. Note: * = Number of studies (k<2) too small to test for small study effects. $ = combined method of two or more single measure methods including self-reported, pill count, checking medical records, and clinic staff monitoring in the whole study process.

| Subgroup                      | No. of studies | Proportion, 95%CI(100%) | Heterogeneity |
|-------------------------------|----------------|-------------------------|---------------|
|                               |                |                         | $i^2$, 95%CI(%)| $H$, 95%CI | $\tau^2$ |
| Pregnant women                |                |                         |               |           |
| Publication year              |                |                         |               |           |
| 2008                          | 3              | 79.18(63.80 to 91.00)   | 90.7(75.5 to 96.4) | 3.27(2.02 to 5.3) | 0.081 |
| 2009                          | 2              | 68.60 (27.10 to 100)    | 99.5          | 14.17     | 1.664 |
| 2011                          | 1              | 85.01(82.96 to 86.95)   | -             | -         | -     |
| 2012                          | 3              | 84.43(65.34 to 96.84)   | 96.2(92 to 98.2) | 5.14(3.53 to 7.48) | 0.148 |
| 2013                          | 4              | 88.11(74.41 to 97.15)   | 98.4(97.4 to 99) | 7.84(6.18 to 9.94) | 0.12  |
| 2014                          | 1              | 95.65(89.27 to 99.45)   | -             | -         | -     |
| Regions                       |                |                         |               |           |
| North-west China              | 1              | 66.23 (63.27 to 69.13)  | -             | -         | -     |
| South-central China           | 3              | 96.05(83.13 to 100)     | 99.5(99.3 to 99.7) | 14.6(12.06 to 17.68) | 0.274 |
| South-western China           | 1              | 85.68(74.81 to 93.93)   | 94.9(91.8 to 96.9) | 4.44(3.49 to 5.66) | 0.126 |
| Trans-regional                | 3              | 66.77(37.46 to 90.32)   | 90.7(75.6 to 96.5) | 3.28(2.02 to 5.31) | 0.125 |
| Sample size                   |                |                         |               |           |
| ≤100                          | 4              | 95.89(87.93 to 99.94)   | 78.9(43.6 to 92.1) | 2.18(1.33 to 3.56) | 0.065 |
| >100                          | 10             | 77.45(66.06 to 87.09)   | 98.6(98.2 to 98.9) | 8.49(7.45 to 9.69) | 0.163 |
| Adherence measure             |                |                         |               |           |
| Single self-reported          | 2              | 94.40(72.45 to 100)     | 90.1          | 3.18      | 0.171 |
| Combined methods$              | 12             | 81.42(71.16 to 89.88)   | 98.4(98 to 98.8) | 7.97(7.04 to 9.02) | 0.174 |
| Quality score of study quality|                |                         |               |           |
| <8                            | 8              | 82.86(64.92 to 95.38)   | 98.7(98.2 to 99) | 8.71(7.52 to 10.08) | 0.338 |
| ≥8                            | 6              | 84.74(79.13 to 89.62)   | 91.2(83.7 to 95.3) | 3.38(2.48 to 4.61) | 0.027 |
| Injection drug users           |                |                         |               |           |
| Publication year              |                |                         |               |           |
| 2008                          | 4              | 67.47(55.36 to 78.52)   | 84.4(60.9 to 93.8) | 2.53(1.6 to 4) | 0.053 |
| 2010                          | 1              | 46.08(36.47 to 55.84)   | -             | -         | -     |
| 2011                          | 1              | 70(57.72 to 81.02)      | -             | -         | -     |
| 2013                          | 3              | 59.34(53.17 to 65.36)   | 0(0 to 89.5)  | 1(1 to 3.09) | 0     |
| Regions                       |                |                         |               |           |
| North-west China              | 2              | 71.61(44.38 to 92.40)   | 92.4          | 3.62      | 0.147 |
| South-central China           | 5              | 64.05(57.24 to 70.60)   | 50.5(0 to 81.8) | 1.42(1.235) | 0.012 |
| South-western China           | 1              | 46.08(36.47 to 55.84)   | -             | -         | -     |
| Trans-regional                | 1              | 56.91(48.04 to 65.56)   | -             | -         | -     |
| Sample size                   |                |                         |               |           |
| ≤100                          | 4              | 69.23(56.37 TO 80.77)   | 78.3(41.4 to 91.9) | 2.14(1.31 to 3.52) | 0.056 |
| >100                          | 5              | 58.22(50.49 to 65.75)   | 71.7(28.7 to 88.8) | 1.88(1.18 to 2.99) | 0.022 |
| Adherence threshold           |                |                         |               |           |
| 90–99%                        | 4              | 67.59(55.65 to 78.49)   | 84.1(60 to 93.7) | 2.51(1.58 to 3.98) | 0.052 |
| 100%                          | 5              | 58.56(50.20 to 66.70)   | 65.2(9 to 86.7) | 1.7(1.05 to 2.74) | 0.023 |
| Adherence measure             |                |                         |               |           |
| Single self-reported          | 5              | 67.54(56.98 to 77.28)   | 80.2(53.3 to 91.6) | 2.24(1.46 to 3.44) | 0.048 |
| Combined methods$              | 4              | 56.75(49.01 to 64.33)   | 58.1 (0 to 86.1) | 1.55(1 to 2.68) | 0.014 |
| Quality score of study quality|                |                         |               |           |
| <8                            | 3              | 66.36 (49.73 to 81.17)  | 72.9(37.8 to 88.2) | 1.92(1.27 to 2.91) | 0.031 |
| ≥8                            | 6              | 61.09(52.78 to 69.10)   | 88.2(67.1 to 95.8) | 2.91(1.74 to 4.86) | 0.077 |
| Children                      |                |                         |               |           |

(Continued)
The use of ART in decreasing mother-to-child transmission of HIV has played an important role in global HIV/AIDS prevention and control. A recent meta-analysis observed a pooled estimate of 62.0% of pregnant women who had more than 80% ART adherence in high-income countries [54]. Our review observed a pooled estimate of nearly 80% of Chinese pregnant women who had 100% ART adherence, which might be due to the Chinese government investing in integrated prevention of mother-to-child transmission (PMTCT). The Chinese government has increased the investment for integrated PMTCT from US$0.9 million in 2003 to US$136.8 million in 2010, resulting in a remarkable increase of ART in HIV-infected pregnant women [55]. In China, PMTCT services were integrated with antenatal and perinatal care, and HIV-infected pregnant women were treated with antiviral drugs when they attended antenatal/perinatal care service. The integration of these health services in terms of HIV prevention may contribute to the maintenance of a high level of ART adherence.

HIV epidemics in China continue to be concentrated among FSWs, IDUs, and MSM, not in the general population; therefore, maintaining high levels of ART adherence in these high-risk populations may be very important for preventing and reducing HIV transmission in China [1]. Some previous reviews have observed that 76% of FSWs worldwide and 72% of IDUs in low- and middle-income countries have adequate ART adherence [2,56]. Our meta-analysis estimated that 62.78% of IDUs had adequate ART adherence in China, which is a very low adherence level compared with that of other low- and middle-income countries. In China, many barriers prevent IDUs from maintaining ART high adherence. For example, poverty can affect adherence by limiting travel to centres for medication, and stigma may also prevent patients from utilizing available free ART services. Several programs, such as needle and syringe exchange programs, have now begun to integrate treatment for opiate addiction into current free ART programs for IDUs in China, which can promote ART adherence. Regarding MSM, no review has assessed ART adherence. Although we observed an encouraging estimate of ART adherence in MSM, this estimate should be interpreted with caution due to the small number of studies. Although exposure among MSM has become the dominant route of HIV transmission, Chinese MSM tend to have very poor access to HIV prevention services, with

Table 2. (Continued)

| Subgroup                | No. of studies | Proportion, 95%CI(100%) | Heterogeneity | I², 95%CI(%) | H, 95%CI | tau²  |
|-------------------------|----------------|-------------------------|---------------|--------------|----------|-------|
|                         |                |                         |               |              |          |       |
| 2007                    | 1              | 93.94(82.59 to 99.89)   | -             | -            | -        | -     |
| 2009                    | 1              | 97.83(90.90 to 1)       | -             | -            | -        | -     |
| 2011                    | 1              | 80.46(71.4 to 88.19)    | -             | -            | -        | -     |
| 2012                    | 1              | 81.63(69.41 to 91.40)   | -             | -            | -        | -     |
| Regions                 |                |                         |               |              |          |       |
| Eastern China           | 1              | 93.94(82.59 to 99.89)   | -             | -            | -        | -     |
| Northwest China         | 1              | 97.83(90.90 to 1)       | -             | -            | -        | -     |
| South-central China     | 2              | 80.92(73.77 to 87.20)   | 75.9(33.6 to 91.2) | 2.04(1.23 to 3.38) | 0.061   |       |
| Quality score of study quality | |                   |               |              |          |       |
| <8                      | 3              | 92.11(80.28 to 99.15)   | 72.9(9 to 92) | 1.92(1.05 to 3.53) | 0.063   |       |
| ≥8                      | 1              | 80.46(71.40 to 88.19)   | -             | -            | -        | -     |

Elderly patients

| Publication year | Proportion, 95%CI(100%) | Heterogeneity | I², 95%CI(%) | H, 95%CI | tau² |
|------------------|-------------------------|---------------|--------------|----------|------|
| 2012             | 69.44(53.28 to 83.58)   | -             | -            | -        | -    |
| 2013             | 95.24(88.28 to 99.39)   | -             | -            | -        | -    |
| 2014             | 96(88.32 to 99.93)      | -             | -            | -        | -    |
only a few national prevention programs targeting this population in China[1]. A very interesting finding in this meta-analysis was that the lowest ART adequate adherence rate was observed in heterosexual transmission group patients. Considerable sexual transmission continues among MSM and high risk heterosexuals in China, therefore we really have to exert more effort and spend more time on the “treatment as prevention” strategy in these high risk populations.

Our study had some limitations. Firstly, a high heterogeneity was observed between studies. Although we performed subgroup analyses according to different high risk populations, publication year, geographical area, sample size, threshold for measurement, adherence assessor and study quality, these factors may be the sources of between-study heterogeneity. However, other unmeasured factors likely affected the detected heterogeneity; unfortunately, we did not obtain sufficient information about these aspects for further analysis. Assuming homogeneity often

| Table 3. Results of Meta-regression for Adherence to Antiretroviral Therapy in China. Note: $, combined method of two or more single measure methods including self-reported, pill count, checking medical records, and clinic staff monitoring in the whole study process. OBS = observational study; INT = interventional study; |
|-----------------|-----------------|-----------------|
| Covariate       | No. of studies  | Univariate analyses |          |          | Multivariable analyses |          |          |
|                 |                 | Coefficient (95% CI) | P value | Variance explained (%) | Coefficient (95% CI) | P value | Variance explained (%) |
| Population (HTG is reference) | 0.028 | 24.46 | 0.032 | 28.14 |
| Former commercial and plasma donors | 2 | 0.09(-0.26 to 0.43) | 0.618 | 0.11(-0.26 to 0.48) | 0.551 |
| Injection drug users | 9 | 0.10(-0.17 to 0.38) | 0.439 | 0.13(-0.16 to 0.41) | 0.367 |
| Pregnant women | 14 | 0.29(0.02 to 0.55) | 0.034 | 0.30(0.03 to 0.72) | 0.029 |
| Men who have sex with men | 2 | 0.33(-0.01 to 0.67) | 0.06 | 0.36(0.01 to 0.72) | 0.047 |
| Children | 4 | 0.36(0.06 to 0.66) | 0.019 | 0.36(0.02 to 0.71) | 0.038 |
| Elderly patients | 3 | 0.35(0.04 to 0.67) | 0.03 | 0.32(0.01 to 0.67) | 0.041 |
| Regions (trans-regional is reference) | 0.791 | -8.13 |
| Eastern China | 2 | 0.06(-0.29 to 0.41) | 0.722 |
| Northwest China | 4 | 0.13(-0.15 to 0.41) | 0.466 |
| South-central China | 17 | 0.14(-0.08 to 0.36) | 0.206 |
| Southwestern China | 8 | 0.17(-0.08 to 0.41) | 0.173 |
| Northern China | 1 | 0.17(-0.28 to 0.62) | 0.447 |
| Study design (INT vs reference) | 0.06(-0.10 to 0.21) | 0.464 | -1.11 |
| Income level | 36 | -0.05(-0.15 to 0.06) | 0.371 | -0.78 |
| Sample size (<100 vs >100) | 36 | -0.14(-0.25 to -0.02) | 0.027 | 10.77 | 0.01(-0.20 to 0.21) | 0.958 |
| Quality score of study quality | 36 | -0.03(-0.07 to 0.00002) | 0.050 | 7.8 | -0.02(-0.07 to 0.02) | 0.328 |
| Year of publication | 36 | 0.02(-0.001 to 0.05) | 0.064 | 6.68 |
| Adherence Assessor(single self-reported vs combined methods$) | 36 | 0.05(-0.03 to 0.17) | 0.197 | 2.35 |
| Threshold for Measurement (%) | 36 | 0.04(-0.05 to 0.12) | 0.355 | -0.17 |

doi:10.1371/journal.pone.0146659.t003
results in a misleading analysis, since heterogeneity is very likely present but undetected, especially for very small meta-analyses\cite{15}. However, we could not check that the findings stand even if we assume high levels of undetected heterogeneity. Furthermore, not enough studies for

\[ \text{Fig 3. Funnel plot for adequate adherence to antiretroviral therapy in China. Panel A: Funnel Plot before study with <30 participants was excluded, Freeman-Tukey Double arcsine transformation was used, Egger'S Linear Regression Test (t = -0.282, P = 0.779); Panel B: Funnel Plot after study with <30 participants was excluded, Egger'S Linear Regression Test (t = -0.365, P = 0.717).} \]
a meta-regression, especially for the multiple regression in our meta-analysis. Small meta-analyses tend not to detect existing heterogeneity and we need to be cautious when they observe apparent homogeneity [57]. Secondly, we did not detect publication bias using Egger’s linear regression test in most of our analyses. However, these results should be interpreted with caution because the detect power is limited, particularly for moderate amounts of bias or meta-analyses based on a small number of small studies (<10). The power to detect publication bias increased with increasing numbers of studies, and publication bias tests only relevant if there are >10 studies otherwise underpowered to detect much and tend to lead to conclusions that are not justified. Furthermore, the risk of publication bias in older studies tends to be higher [58], while we did not find that older studies show larger effects. Thirdly, our results could be altered by a selection bias because different number of studies on ART adherence performed in different populations (pregnant women, children), which may impact the results. In 2003, China initiated its first PMTCT programme in eight cities which provided free HIV testing and antiretroviral (ARV) treating and/or prophylaxis through the antenatal care network. This national health service was the most widely covered and completed, with a high follow-up rate. Therefore, studies on HIV prevention and control among pregnant women were easily conducted, and a large number of individual studies related to PMTCT programmes were performed in China. Nevertheless, there was no national health service like antenatal care network to integrate HIV antiretroviral (ARV) treating and/or prophylaxis through the antenatal care network. This national health service was the most widely covered and completed, with a high follow-up rate. Therefore, studies on HIV prevention and control among pregnant women were easily conducted, and a large number of individual studies related to PMTCT programmes were performed in China. Nevertheless, there was no national health service like antenatal care network to integrate HIV antiretroviral (ARV) treating and/or prophylaxis among other populations such as elderly people, which make it more difficult to conduct studies among these populations. Therefore, selection bias due to the substantially differences in the numbers of studies would be a limitation in this meta-analysis. The last, the single study conducted by Liu X et al. [26] used the ‘blood drug concentration’, one of the most accurate ways of assessing adherence, to assess adherence in this meta-analysis. However, most of the studies included used self-reported method that may introduce information bias or recall bias, which may result in over-estimation of the levels of ART adherence.

**Conclusion**

In conclusion, our meta-analysis found remarkable variations in adherence rate between different high risk populations, with lower adherence in HTG, FCPD and IDU, and high levels of adherence in elderly patients, children, MSM, and pregnant women. ART adherence in some high-risk population, especially in HTG, was significantly below the recommended level for maintaining virologic suppression. It is crucial to develop comprehensive intervention strategies to promote ART adherence in these high-risk populations and effectively protect against the spread of the HIV/AIDS in China.
Acknowledgments

The authors would like to thank all researchers and participants for their valuable contributions to this article.

Author Contributions

Conceived and designed the experiments: ZH JSY. Performed the experiments: WFZ LL ZM CXZ. Analyzed the data: ZH CXZ. Contributed reagents/materials/analysis tools: JSY. Wrote the paper: ZH CXZ.

References

1. Maartens G, Celum C, Lewin SR (2014) HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 384: 258–271. doi:10.1016/S0140-6736(14)60164-1 PMID: 24907868
2. Mountain E, Mishra S, Vickerman P, Pickles M, Gilks C, Boily MC. (2014) Antiretroviral therapy uptake, attrition, adherence and outcomes among HIV-infected female sex workers: a systematic review and meta-analysis. PLoS One 9: e108545.
3. Nachega JB, Marconi VC, van Zyl GU, Gardner EM, Preiser W, Hong SY, et al. (2011) HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets 11: 167–174. PMID: 21406048
4. Ortego C, Huedo-Medina TB, Llorca J, Sevilla L, Santos P, Rodriguez E, et al. (2011) Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav 15: 1381–1396. doi:10.1007/s10461-011-9942-x PMID: 21468660
5. Zhang L, Chow EP, Jing J, Zhuang X, Li X, Gorgens M, et al. (2013) HIV prevalence in China: integration of surveillance data and a systematic review. Lancet Infect Dis 13: 955–963. doi:10.1016/S1473-3099(13)70245-7 PMID: 24107261
6. Li ZJ (2015) Adherence to Antiretroviral therapy adherence and its influencing factors for prevention of mother to child transmission of HIV. Medical Information 28: 317–318.
7. Qiao JK (2014) Effect analysis of free antiretroviral treatment among MSM with AIDS in Yuncheng. Chin J AIDS STD 20: 426–430.
8. Liu MR (2014) Efficacy analysis of nursing care for promoting adherence to antiretroviral therapy on elderly HIV/AIDS patients. Medicine and people 27: 28.
9. Ye HL, Zhai CH, Wei XB (2013) Observation and nursing care of AIDS patients among IDUs during antiretroviral therapy. Chinese Nursing Research 27: 4055–4057.
10. Wu HP, Zheng JR, Yang HX (2013) Analysis on regular medicating and influencing factors for prevention mother-infant-transmission of HIV/AIDS in highly prevalent areas. Matern Child Health J 28: 1313–1316.
11. Wang Q, Fang LW, Wang LH, Wang AL, Wu JL, Wang F, et al. (2013) Trends of applying antiretroviral drugs over time among HIV infected pregnant women and the infants. Chin J AIDS STD 19: 393–395.
12. Qin YL, Chen AL (2013) The effect of health administration on the treatment compliance of the HIV/AIDS patients receiving methadone maintenance treatment (MMT). Modern Hospital 13: 147–149.
13. Liu JR, Lei RH, Qin YH (2013) The effect of consultation prior to antiviral therapy on adherence of elderly patients infected with HIV/AIDS. Medical Innovation of China 10: 152–154.
14. Liu J, Liu ZF, Wang FY, Zhao DC, Dou ZH, Zhang FJ, et al. (2013) Efficacy evaluation of HAART among IDUs in minority regions and its impact factors. Chin J AIDS STD 19: 2–5.
15. Chen SP, Ning YF, Li LX, Cui L, Tan YH (2013) The effects of continuous nursing on antenatal care of HIV-infected pregnant women. Int J Nurs 01: 72–74.
16. Ailika S, Cui D, Maimaitiming A, Guan LL, Wang L (2013) Analysis on anti HIV drug application among HIV positive mothers and their children in Xinjiang, 2010–2012. Chinese Journal of Health Education 29: 687–689.
17. Zhou YF, Gao MX, Sun YH, Tang H, Fu Y (2012) Nursing of AIDS patients under antiretroviral therapy among MSM and analysis of their psychological status Chin J AIDS STD 18: 746–748.
18. Yuan Y, Liu HW, Wang XY, Liu CH, Yang LT, Zheng BF, et al. (2012) Study on prevalence of HIV-1 drug resistance in AIDS former blood donors reveiving to HAART in Henan province. Modern Preventive Medicine 39: 5954–5956.
19. Wei XB, Zhai CH (2012) Influencing factors and nursing counter-measures of compliance of antiretroviral treatment of children with AIDS. Chinese Nursing Research 26: 842–843.
20. Li AJ, Wang YZ (2012) Influencial factors of standard medication in preventing mother-to-child transmission of HIV. Chin J Derm Venereol 26: 516–517+533.
21. Hu HH (2012) Effect of prevention of mother to child transmission of HIV with Triple-antiretroviral regimen: Kunming Medical University.
22. Gui XZ, Qiu H, Qin T (2012) Study on the effectiveness of blocking of maternal-neonatal transmission for HIV-infected pregnant women. Matern Child Health Care of China 27: 4683–4686.
23. Deng MH, Qin SZ, Zhou SY, Liang FL, Yu F (2012) The effects of nursing care on adherence to antiretroviral therapy on elderly HIV/AIDS patients. Chinese and Foreign Medical Research 10: 70–71.
24. Wang Q (2011) The effectiveness evaluation on antiretroviral medicine for prevention mother-infant transmission of HIV/AIDS. M.Sc. Thesis, Chinese Center for Disease Control and Prevention. Available: http://www. jylw.com/25/wz157675.html.
25. Su FQ, Lu ZX, Li GF (2011) Effect of nursing intervention on antiviral treatment compliance of injection drug users infected with HIV/AIDS. Guangxi Medical Journal 33: 1662–1663.
26. Liu X, Zhao Y, Cheng YW, Mo WW, Sun X, Li CM, et al. (2011) The application of plasma drug monitoring in pediatric HIV/AIDS patient antiretroviral therapy adherence monitoring. Chin J Lad Med 34: 542–545.
27. Yang CB, Gu XD, Luo XW, Liang C, Ceng YH (2010) Effectiveness of highly active antiretroviral therapy for injection drug users with HIV/AIDS: A report of 102 case. Chinese General Practice 13: 3188–3190.
28. Chang YL, Zhou KW, Duan AX, Zheng WW (2010) Analysis of clinical data and adherence to antiretroviral therapy in 46 HIV-infected childhood patients in Yining city. Xinjiang Medical Journal 11: 78–80.
29. Wang YZ, Li Y, Jiang CQ, Zheng M, Zhang Y, Xiong YH, et al. (2009) Cross-sectional study on rates and influential factors of standard medication for antiretroviral therapy in preventing mother-to-child transmission of HIV. Chin J Prev Med 04: 277–281.
30. Wang LH, Fang LW, wang Q, Jiang Y, Gong CY, Zhang L, et al. (2009) Effectiveness evaluation of different interventions for prevention of mother to child transmission of HIV/AIDS in China. Chin J AIDS STD 15: 352–355.
31. Pang J (2009) The model of infectious hospital for prevention of mother to child transmission of AIDS. Youjiang national medical journals 03: 432–433.
32. Lu J (2009) Prospective cohort study among injection drug users who accepted highly active antiretroviral therapy in China: Chinese Peking Union Medical College.
33. Zhou J (2008) Effects of comprehensive family intervention on adherence to HAART and treatment outcomes among HIV-infected injection drug users. M.Sc. Thesis, Central South University. Available: http://www.doc88.com/p-5866180557488.html
34. Wang YZ, Li Y, Zhang Y, Luo XY, Jiang CQ, Ye X, et al. (2008) Compliance and related factors of antiretroviral therapy in preventing mother-to-child transmission of HIV. Chinese Journal of Maternal and Child Health Research 23: 407–410.
35. Wang YZ, Li Y, Zhang Y, Luo XY, Jiang CQ, Ye X, et al. (2008) Compliance and related factors of antiretroviral therapy in preventing mother-to-child transmission of HIV. Chinese Journal of Woman and Child Health Research 19: 407–410.
36. Wang HH, Zhou J, Huang L (2008) Adherence to highly active antiretroviral treatment and related factors in drug users with HIV/AIDS. Chin J Behavioral Med Sci 17: 881–883.
37. Lu J, Liu ZF, Ma Y, Zhang FJ, Zhao Y, Li ZL, et al. (2008) Effectiveness of highly active antiretroviral therapy in 62 injection drug uses. Chin J AIDS STD 14: 569–571.
38. Yu RH (2007) The adherence to antiretroviral therapy and associated factors of HIV-infected former commercial and plasma donors in rural China. M.Sc. Thesis,Chinese Peking Union Medical College. Available: http://www.doc88.com/p-749875088234.html.
39. Liu AW, Ji GP, Xiao YK, Wu JJ, Qin YZ (2007) Effects of highly active antiretroviral therapy for children infected with AIDS. Anhui J Prev Med 20: 414–416.
40. Dong XB (2014) Analysis of adherence to antiretroviral therapy among 285 HIV patients. Medical information 27: 612.
41. Lee SS, Ma K, Chu EK, Wong KH (2007) The phenomenon of missing doses in a cohort of HIV patients with good adherence to highly active antiretroviral therapy. Int J STD AIDS 18: 167–170. PMID: 17362548
42. Ministry of Civil Affairs of the People's Republic of China. Administrative division of the People's Republic of China. Available: http://www.zqhorgcn/ accessed %2010%20May%202015.
43. Research centers of Chinese livable city. GDP and per capital GDP of Chinese provinces. Available: www.elivecity.cn. Accessed 10 May 2015.
44. Rostom A, Dube C, Cranney A. Celiac Disease. Rockville (MD): Agency for Healthcare Research and Quality (US). Available: http://www.ncbi.nlm.nih.gov/books/NBK35156/ accessed May 10, 2015.

45. Brockwell SE, Gordon IR (2001) A comparison of statistical methods for meta-analysis. Stat Med 20:825–840. PMID:11252006

46. Miller J (1978) The inverse of the Freeman-Tukey double arcsine transformation. Am Stat 32:138.

47. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. PMID:12958120

48. Mittiböck M, Heinzl H (2006) A simulation study comparing properties of heterogeneity measures in meta-analyses. Stat Med 25:4321–4333. PMID:16991104

49. Dai F, Liang XM, Ao XM (2014) Nursing care for promoting adherence to antiretroviral therapy on elderly HIV/AIDS patients. Journal of Qilu Nursing 20: 77–79.

50. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634. PMID: 9310563

51. Mhaskar R, Alandikar V, Emmanuel P, Djulbegovic B, Patel S, Patel A, et al. (2013) Adherence to antiretroviral therapy in India: a systematic review and meta-analysis. Indian J Community Med 38: 74–82. doi:10.4103/0970-0218.112435 PMID: 23878418

52. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. (2006) Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 296: 679–690. PMID: 16896111

53. Ortego C, Huedo-Medina TB, Vejo J, Llorca FJ (2011) Adherence to highly active antiretroviral therapy in Spain. A meta-analysis. Gac Sanit 25: 282–289. doi: 10.1016/j.gaceta.2010.10.016 PMID: 21546132

54. Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, et al. (2012) Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS 26: 2039–2052. doi: 10.1097/QAD.0b013e328359590f PMID: 22951634

55. Zeng H, Chow EP, Zhao Y, Wang Y, Tang M, Li L, et al. (2015) Prevention of mother-to-child HIV transmission cascade in China: a systematic review and meta-analysis. Sex Transm Infect. 2015 May 2. pii: sextrans-2014-051877. doi: 10.1136/sexttrans-2014-051877

56. Feeleymer J, Des Jarlais D, Arasteh K, Uusikula A (2015) Adherence to antiretroviral medications among persons who inject drugs in transitional, low and middle income countries: an international systematic review. AIDS Behav 19: 575–583. doi: 10.1007/s10461-014-0928-3 PMID: 25331268

57. Kontopantelis E, Springate DA, Reeves D (2013) A re-analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta-analyses. PLoS One 8:e69930. doi: 10.1371/journal.pone.0069930 PMID: 23922860

58. Kicinski M, Springate DA, Kontopantelis E (2015). Publication bias in meta-analyses from the Cochrane Database of Systematic Reviews. Stat Med 34:2781–93. doi: 10.1002/sim.6525 PMID: 25988604